RESUMO
The Oklahoma Thrombotic ThrombocytopenicPurpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry has enrolled all 335 consecutive patients from central, western and southeastern Oklahoma who had their first episode of clinically diagnosed TTP or HUS from 1989 through 2005; follow-up is complete for 333 patients. Identifying all patients is possible since plasma exchange is the essential treatment for all adults and some children with these disorders and since the Oklahoma Blood Institute (OBI) is the sole provider of plasma exchange services for this region. Patients in the Oklahoma TTP-HUS Registry have come from 46 counties and have been treated in 16 hospitals; 227 physicians have provided the principal care for these patients. A support group formed in 1996 has met 3 times each year, averaging 17 former patients plus 16 additional family members and friends. Registry data are an important source of information for physicians and their patients, providing a complete community perspective of these uncommon disorders.
Assuntos
Serviços de Saúde Comunitária , Síndrome Hemolítico-Urêmica/epidemiologia , Púrpura Trombocitopênica Trombótica/epidemiologia , Sistema de Registros , Adolescente , Adulto , Criança , Feminino , Síndrome Hemolítico-Urêmica/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Oklahoma/epidemiologia , Avaliação de Programas e Projetos de Saúde , Estudos Prospectivos , Púrpura Trombocitopênica Trombótica/terapia , Grupos de AutoajudaRESUMO
A 32-year-old man was newly diagnosed with acute myelocytic leukemia, classified as acute myeloblastic leukemia with maturation (AML-M2) according to the French-American-British classification system. Conventional chromosome analysis before chemotherapy treatment revealed an abnormal karyotype: a possible segmental duplication of 11q23, plus a translocation between chromosomes 15 and 17 [t(15;17) (q22;q21.1)] in the majority of cells analyzed. Fluorescence in situ hybridization analysis using commercially available probes confirmed the cytogenetic findings. To our knowledge, this is the first report of a combination of t(15;17) and a segmental duplication of 11q23 in a patient with AML-M2.
Assuntos
Cromossomos Humanos Par 11/genética , Cromossomos Humanos Par 15/genética , Cromossomos Humanos Par 17/genética , Duplicação Gênica , Leucemia Mieloide Aguda/genética , Translocação Genética/genética , Adulto , Medula Óssea/patologia , Humanos , Hibridização in Situ Fluorescente , MasculinoRESUMO
Blood donor screening and blood collection are two of the donor-focused activities inherent in the process of maintaining an adequate blood supply. Donor screening represents procedures to provide safety for both donors as well as recipients. Donor medical history questions are so cumbersome that self-administered manual, computer-assisted, or on-line donor questions are under consideration in order to reduce time involved in the screening process. Blood collection procedures remain primarily based on whole blood donations, but apheresis donations are increasing steadily. The yield of multiple transfusible units per donation, as well as quality and reproducibility per product, support the use of apheresis procedures or other automated whole blood techniques to help offset blood shortages.